PolyPeptide Group AG (SWX:PPGN)

Market Cap	1.15B +106.1%
Revenue (ttm)	362.47M +15.6%
Net Income	-19.71M
EPS	-0.60
Shares Out	33.01M
PE Ratio	n/a
Forward PE	60.54
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,292
Average Volume	106,583
Open	34.75
Previous Close	34.70
Day's Range	34.10 - 34.95
52-Week Range	16.50 - 38.80
Beta	0.86
RSI	63.45
Earnings Date	Aug 13, 2026

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, Asia Pacific, and internationally. It develops and manufactures synthetic peptides used as active pharmaceutical ingredients or intermediates in therapeutic products. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices, as well as development and analytical services. The company serves academic, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,440
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2025, PolyPeptide Group AG's revenue was 389.33 million, an increase of 15.60% compared to the previous year's 336.79 million. Losses were -21.17 million, 8.20% more than in 2024.

Financial numbers in EUR